The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer

被引:14
作者
Balch, Curtis [3 ]
Nephew, Kenneth P. [1 ,2 ,3 ]
机构
[1] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Med Sci Program, Bloomington, IN 47408 USA
[2] Indiana Univ Sch Med, Dept Med, Dept Obstet & Gynecol, Bloomington, IN 47408 USA
[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
HISTONE DEACETYLASE INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLTRANSFERASE 1; TISSUE-GROWTH-FACTOR; SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; CHEMOTHERAPY RESISTANCE; EPIGENETIC REGULATION; TRANSCRIPTION FACTOR; INTEGRATED ANALYSIS;
D O I
10.3233/CBM-2011-0214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The term "epigenetics" refers to DNA sequence-independent events that regulate gene expression, including DNA methylation, modifications to histone proteins, and microRNA-associated post-transcriptional control of protein translation. Epigenetic aberrations are now considered a defining characteristic of numerous human pathologies, including cancer. However, in contrast to DNA sequence mutations, many oncogenic epigenetic modifications are potentially reversible, with studies now showing numerous tumor cell types to possess remarkable phenotypic "plasticity," strongly supporting possible reversion of their malignant status. The "epigenome" of one such malignancy, ovarian cancer, has now been studied in depth, with specific epigenetic alterations correlated with tumor initiation, progression, metastasis, and therapy resistance. Ovarian cancer is the most lethal malignancy of the female reproductive tract, largely due to lack or diagnoses of early-stage disease and the eventual develoment of drug resistance; thus, reliable early detection biomarkers and alternative therapies are urgently needed. In this chapter, we discuss the epigenetics of ovarian cancer, including its likely role in the establishment of "cancer stem cells," i.e., highly tumorigenic progenitor cells believed to be largely or solely responsible for the propagation of malignant, chemotherapy-resistant and metastatic disease. Improved understanding of these gene-regulatory phenomena could likely result in improved detection and survival of this highly destructive malignancy.
引用
收藏
页码:203 / 221
页数:19
相关论文
共 204 条
  • [1] Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells
    Abbosh, Phillip H.
    Montgomery, John S.
    Starkey, Jason A.
    Novotny, Milos
    Zuhowski, Eleanor G.
    Egorin, Merrill J.
    Moseman, Annie P.
    Golas, Adam
    Brannon, Kate M.
    Balch, Curtis
    Huang, Tim H. M.
    Nephew, Kenneth P.
    [J]. CANCER RESEARCH, 2006, 66 (11) : 5582 - 5591
  • [2] Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules
    Adair, Sara J.
    Hogan, Kevin T.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (04) : 589 - 601
  • [3] Ovarian cancer: Strategies for overcoming resistance to chemotherapy
    Agarwal, R
    Kaye, SB
    [J]. NATURE REVIEWS CANCER, 2003, 3 (07) : 502 - 516
  • [4] DNA methylation and ovarian cancer
    Ahluwalia, A
    Yan, P
    Hurteau, JA
    Bigsby, RM
    Jung, SH
    Huang, THM
    Nephew, KP
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (02) : 261 - 268
  • [5] Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer
    Ahmed, N.
    Abubaker, K.
    Findlay, J.
    Quinn, M.
    [J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (03) : 268 - 278
  • [6] Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance
    Alvero, Ayesha B.
    Chen, Rui
    Fu, Han-Hsuan
    Montagna, Michele
    Schwartz, Peter E.
    Rutherford, Thomas
    Silasi, Dan-Arin
    Steffensen, Karina D.
    Waldstrom, Marianne
    Visintin, Irene
    Mor, Gil
    [J]. CELL CYCLE, 2009, 8 (01) : 158 - 166
  • [7] *AM CANC SOC, 2010, WHAT AR KEY STAT OV
  • [8] [Anonymous], FDA CLEARS TEST OV C
  • [9] Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells
    Baba, T.
    Convery, P. A.
    Matsumura, N.
    Whitaker, R. S.
    Kondoh, E.
    Perry, T.
    Huang, Z.
    Bentley, R. C.
    Mori, S.
    Fujii, S.
    Marks, J. R.
    Berchuck, A.
    Murphy, S. K.
    [J]. ONCOGENE, 2009, 28 (02) : 209 - 218
  • [10] Antimitogenic and chernosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
    Balch, C
    Yan, P
    Craft, T
    Young, S
    Skalnik, DG
    Huang, THM
    Nephew, KP
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (10) : 1505 - 1514